Heron Therapeutics (HRTX) Debt Ratio (2011 - 2026)

Heron Therapeutics (HRTX) has reported Debt Ratio for 15 consecutive years, with 0.43 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Debt Ratio fell 33.23% year-over-year to 0.43; the trailing twelve-month figure through Jun 2026 stood at 0.43 (down 33.23% YoY), and the FY2025 full-year result was 0.42, up 292.85% from the prior year.
• Debt Ratio eased to 0.43 in Q2 2026 per HRTX's latest filing, from 0.44 in the prior quarter.
• Across five years, Debt Ratio topped out at 0.65 in Q2 2025 and bottomed at 0.1 in Q3 2023.
• Historically, Debt Ratio has averaged 0.26 across 4 years, with a median of 0.11 in 2024.
• The sharpest annual moves came in 2025 and 2026: Debt Ratio surged 471.56% in 2025, then plunged 33.23% in 2026.
• Over 4 years, Debt Ratio stood at 0.11 in 2023, then retreated by 1.56% to 0.11 in 2024, then surged by 292.85% to 0.42 in 2025, then grew by 2.21% to 0.43 in 2026.
• According to Business Quant data, Debt Ratio over the past three periods registered 0.43, 0.44, and 0.42 for Q2 2026, Q1 2026, and Q4 2025 respectively.